Gregory M. Lanza, MD, PhD, FACC
Professor of Medicine, Biomedical Engineering, and Biology and Biomedical Sciences; Oliver M. Langenberg Chair, Distinguished Professor of the Science and Practive of Medicine; Co-Founder, Chief Scientific Officer and Board Member, Kereos, Inc., St. Louis, MO
- Phone: 314-454-8635
Related Links
- Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN)
- Physician Profile
- Research Profile
Education
- Bachelor of Arts: Colby College, Waterville, MN (1975)
- Masters of Science: Department of Poultry Science, University of Georgia, Athens, GA (1978)
- Doctor of Philosophy: Department of Poultry Science, University of Georgia, Athens, GA (1981)
- Doctor of Medicine: Northwestern University Medical School, Chicago, IL (1992)
- Residency, Medicine: Department of Medicine, Barnes Hospital, Washington University Medical Center, St. Louis, MO (1994)
- Fellowship, Cardiology: Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO (1999)
Board Certifications
- Cardiovascular Disease
Recognition
- Phi Kappa Phi Honor Society
- Gamma Sigma Delta Agricultural Honor Society
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- NCI Unconventional Innovation Program Awards, 2000-2003, 2002-2005, 2003-2006
- American Heart Association, Missouri Affiliate – Beginning Grant, 1999-2001
- Barnes-Jewish Hospital Research Foundation Award, 1999-2001
- American College of Cardiology, Searle Career Development Award, 2000
Clinical Interests
Heart disease, molecular imaging, in vivo molecular imaging, site targeted ultrasound; supervising and interpreting diagnostic tests, such as echocardiograms, stress echocardiograms, treadmill stress test, holter, event and loop monitors
Research Interests
Dr. Lanza is a Director of CTRAIN, which is installing a clinical MRI as part of a WU-United Imaging in Healthcare collaboration. The program will be IAC accredited and heavily focused on cardio-oncology. The primary research will be to utilize MRI to assess cardiac toxicity imparted from cancer therapeutics, e.g. TKI, anthracyclines, PD-1, and secondary disease manifestations, e.g., amyloid. in myeloma. The program seeks to simplify MR acquisition and reporting techniques and to project patient therapeutic outcomes using Artificial Intelligence. AI will be used to assist in hybridizing myocardial tissue characterization data, reflective of inflammation, fibrosis, and inflitrate, with demographic and blood based clinical pathology indicators.
In addition, Dr. Lanza has coinvented numerous nanoparticle platforms for molecular imaging with MRI, ultrasound, CT, optical, and photoacoustics. In addition, he has developed nanoparticle platforms and compatible prodrugs to address a variety of unmet medical needs in cardiovascular disease, cancer, and arthritis.